[{"id": 10611, "archived": false, "name": "Advocacy Resources", "action_center": 1681, "path": "/advocacy-resources/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "IDSA/HIVMA Advocacy Resources", "content": ""}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 1, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3015, "archived": false, "name": "Global ID", "action_center": 1681, "path": "/Global_ID/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Global HIV &TB", "content": "

IDSA\u2019s\nglobal health advocacy work focuses on promoting sufficient US investment in\nglobal infectious diseases responses and research, and in using the voices of\nphysician scientists to inform multilateral and national global health policies\nand practices. Working in coalition with global health partners, IDSA is a\ntrusted leader in shaping and advancing international and national policies and\ninvestments in global HIV, TB, global health security, antimicrobial resistance\nand emerging infections.

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n

IDSA advocates for a comprehensive One Health (including\nhuman, animal and environmental health) approach to combat antimicrobial\nresistance through stewardship, research, surveillance, prevention, global\ncoordination and the development of new antibiotics and other therapies,\ndiagnostics and vaccines. A strong infectious diseases workforce is central to\nthese efforts. IDSA advocates for significant increases in federal funding to\nadvance these solutions, including through the National Action Plan to Combat\nAntibiotic Resistant Bacteria.

IDSA is advocating for passage of the Pioneering\nAntimicrobial Subscriptions to End Upsurging Resistance (PASTEUR), a bipartisan\nbill that IDSA helped to develop. PASTEUR would change the way the federal\ngovernment pays for critically needed new antibiotics. Under PASTEUR, the\nfederal government would enter into contracts with antibiotic innovators to\nprovide set payments, rather than paying by volume. This approach aligns with\nstewardship principles and would provide the predictable return on investment\nneeded to revitalize the antibiotics market. PASTEUR would also establish a new\ngrant program to support antimicrobial stewardship programs in health care\nfacilities.

IDSA convenes the Stakeholder Forum on Antimicrobial\nResistance (S-FAR) a coalition of over 120 organizations representing\nclinicians, scientists, public health, patients and industry. Through S-FAR,\nIDSA leads a diverse set of partners to\nadvance shared policy priorities that combat antimicrobial resistance.

\n\n\n\n

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n

"}, "widgetType": 18}, {"props": {"content": "Tweets by HIVMA \n

"}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 4, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3012, "archived": false, "name": "Home", "action_center": 1681, "path": "/home_page/", "title": "IDSA HIVMA Action Center", "page_restriction_type": 1, "widgets": [{"props": {"title": "Welcome to the IDSA/HIVMA Action Center", "content": "

Constituent input is critical to the work of Congress. This Action Center allows IDSA and HIVMA members and the general public to influence infectious diseases policymaking in Congress and the Administration. Advocates can use this action center to take action on all current advocacy campaigns and learn more about IDSA/HIVMA's key policy issues. As ID/HIV experts, you have an important role in advancing IDSA/HIVMA's policy priorities and can serve as a needed resource for lawmakers. Through advocacy, you can extend your reach beyond the patients you serve.

If you haven't already, sign up for our Member Advocacy Program (MAP) to become a part of IDSA/HIVMA's advocacy team.

"}, "widgetType": 4}, {"props": {"title": "Take Action!", "content": "There are no active campaigns at the moment. If you haven't already, sign up for IDSA/HIVMA's Member Advocacy Program so you can be notified the next time an advocacy campaign is available!"}, "widgetType": 101}, {"props": {"id": 6322, "title": "Become an IDSA/HIVMA Advocate!", "content": ""}, "widgetType": 9}, {"props": {"title": "IDSA's and HIVMA's In-District Meeting Resource", "content": "

Click here to view the In-District Meeting Resource

"}, "widgetType": 4}], "requires_login": false, "widget_layout_type": 10, "custom_javascript": "", "custom_css": "img { \n\n border-radius: 15%; \n\n overflow: hidden; /* prevents the corners from showing through if image is inside a container */ \n\n} \n", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 8753, "archived": false, "name": "Find My Legislators", "action_center": 1681, "path": "/legislators/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Find My Legislators"}, "widgetType": 103}], "requires_login": false, "widget_layout_type": 1, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 2835, "archived": false, "name": "Take Action", "action_center": 1681, "path": "/takeaction/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"id": 6322, "title": "Sign Up to Take Action!", "content": "

", "post_text": "Enter your contact information and address below to receive text alerts and information to reach your congressional representatives on IDSA and HIVMA priority issues."}, "widgetType": 9}, {"props": {"content": ""}, "widgetType": 101}], "requires_login": false, "widget_layout_type": 2, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3017, "archived": false, "name": "Immunizations & Vaccines", "action_center": 1681, "path": "/Immunizations_vaccines/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Immunizations & Vaccines", "content": "

IDSA works independently and through coalitions with like-minded organizations to monitor and favorably impact immunization policy and programs as well as to support continued investments in vaccine research and development which is essential to bring new and improved vaccines to market. U.S. policymakers must be vigilant in working to improve and ensure the availability of these critical public health tools.

While the United States has made significant progress toward eliminating vaccine-preventable diseases among children, similar successes have not yet occurred for adults and adolescents. Unacceptably low immunization rates exist among many adults and adolescents in the U.S. To combat this failure, IDSA developed a set of policy principles and recommendations to strengthen adult and adolescent immunizations, and we are working with federal and state partners to move these ideas forward.

Healthcare personnel (HCP) are at risk for exposure to vaccine-preventable diseases and possible transmission to patients, their families, other personnel, and local communities. IDSA supports mandatory immunization of HCP according to recommendations of the Advisory Committee for Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC).

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n

"}, "widgetType": 18}, {"props": {"content": "Tweets by HIVMA \n

"}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 4, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3019, "archived": false, "name": "Federal Funding", "action_center": 1681, "path": "/Federal_Funding/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Federal Funding", "content": "

\ufeffToday\u2019s investment in ID and HIV research;\npublic health and prevention; and development of new drugs, vaccines and\ndiagnostics will pay significant dividends in the future. Such investments can\nprevent needless deaths, dramatically reduce health care costs, and\nimprove the quality of life for millions of Americans and others around\nthe world. IDSA and HIVMA support appropriate funding for domestic\nand international programs including those at the:

National Institutes of Health
- National Institute of Allergy\n and Infectious Diseases
- Fogarty International\n Center
- Office of AIDS Research
Centers for Disease Control and\n Prevention
Food and Drug\n Administration
Health Resources Services\n Administration
- Continued robust funding for\n the Ryan White Program at the HIV/AIDS Bureau (HAB)
- Continued robust funding for\n the Bureau of Primary Care (Community Health Centers)
U.S. Department of State
U.S. Agency for International\n Development
Biomedical Advanced Research\n and Development Authority (BARDA)

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n

"}, "widgetType": 18}, {"props": {"content": "Tweets by HIVMA \n

"}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 4, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3014, "archived": false, "name": "HIV in the U.S.", "action_center": 1681, "path": "/HIV/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "HIV in the U.S.", "content": "

With significant advances in HIV prevention and treatment, progress\nhad been made in reducing new HIV infections and improving health outcomes for\npeople with HIV. An estimated 35% of people with HIV, however, are still not\nbenefiting from HIV treatment and significant\ndisparities persist among Black, Indigenous and other communities of color.\nBlack/African American individuals represent 13% of the United States\npopulation and 41% of new HIV infections and the Latinx community represents 18%\nof the U.S. population and 23% of new HIV infections. And while death\nrates due to HIV have declined, HIV-related deaths continue to be highest\namong multi-racial and Black populations.

Addressing the root causes of health inequities, including systemic\nracism, is fundamental to ending HIV as an epidemic in the U.S., and HIVMA strongly\nsupports these efforts. HIVMA\u2019s 2021 advocacy portfolio also includes:

Advancing the Ending\nthe HIV Epidemic initiative and ensuring funding to support it;

Sustaining and growing the HIV workforce by\nadvancing the BIO Preparedness Workforce Act;

\nIncreasing access to health care services and\nhealth coverage for people with HIV and at risk for HIV, including by strengthening\nthe Affordable Care Act and the Medicaid Program;

\nEnsuring a robust Ryan White HIV/AIDS Program\nthrough our Ryan\nWhite Medical Providers Coalition;

\nSecuring sufficient federal funding for HIV,\nSexually Transmitted Infections and viral hepatitis and related programs;

\nSupporting efforts to advance a comprehensive\nand evidence-based response to the opioid and substance use epidemics to\nreduce illness and death due to substance use and the infections linked to\nsubstance use.

HIVMA is a partner in IDSA\u2019s global health advocacy. Also\nsee HIVMA\u2019s Policy\nPosition Statements to learn where we stand on key issues affecting people\nwith HIV and the HIV clinical and research communities.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

"}, "widgetType": 4}, {"props": {"title": "", "content": "Tweets by IDSAInfo \n

"}, "widgetType": 18}, {"props": {"title": "", "content": "Tweets by HIVMA \n

"}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 4, "custom_javascript": "", "custom_css": ".page-col-1 {z-index: 100 !important}", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3016, "archived": false, "name": "Diagnostics", "action_center": 1681, "path": "/diagnostics/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Diagnostics", "content": "

Despite advances in diagnostic technology, there is an urgent need for tests that are easy to use, identify the microbe causing the infection, determine whether it is drug resistant, and provide results faster than current tests. Faster, more accurate tests would help ensure that patients are receiving the best treatment for a variety of infectious diseases, guide more effective infection control practices, and improve the tracking of outbreaks. Better tests would also help protect our dwindling supply of effective antibiotics by reducing their misuse.

The IDSA report, Better Tests Better Care, Improved Diagnostics for Infectious Diseases, recommends the following policy interventions:

Stimulate Diagnostics Research and Development (R&D)

Address Regulatory Challenges to Diagnostics R&D

Ensure Appropriate Levels of Reimbursement for Diagnostics Testing

Encourage Adoption of New Tests

Educate Healthcare Providers on the Use of Diagnostics

Expedite Integration of Improved Diagnostic Tests into Patient Care

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n

"}, "widgetType": 18}, {"props": {"content": "Tweets by HIVMA "}, "widgetType": 18}], "requires_login": false, "widget_layout_type": 4, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3318, "archived": false, "name": "Ryan White Medical Providers Coalition ", "action_center": 1681, "path": "/RWMPC/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"text": "At a time when there is the political will to end HIV as an epidemic in the U.S. and we have the tools to accomplish this\ngoal, we face an HIV workforce shortage that has been compounded by the COVID-19 pandemic. H.R. 7543, the HIV\nEpidemic Loan-Repayment Program (HELP) Act, introduced by Rep. John Lewis, would address critical workforce\nshortage through loan repayment relief for HIV clinicians and dentists", "title": "The HIV Epidemic Loan Repayment Program", "buttonUrl": "https://www.hivma.org/globalassets/idsa/homepage/2020-july-help-act-talking-points.pdf?e=KqwYd8", "mediaType": 1, "buttonText": "HELP Act Talking Points", "isLeftAligned": true, "useBackgroundColor": false}, "widgetType": 23}, {"props": {"text": "Since 2013, new HIV diagnoses have plateaued at around 38,000 per year. This comes after years of\nsteady progress in combating the disease and new science that increases the effectiveness of treating\nand preventing HIV. There is now scientific and community consensus that if a person living with HIV is\non treatment and achieves viral suppression, they cannot pass HIV on to a partner. Additionally, people\nwho are HIV-negative have an ever-expanding toolbox of HIV prevention options, most notably preexposure prophylaxis (PrEP), a once daily medication that effectively prevents HIV.\nOur scientific knowledge of HIV treatment, prevention and epidemiology has never been stronger, but\nprogress, until recently, has stalled. Over the past two years, a concerted effort to target resources\nwhere they can be most effective has occurred through the Ending the HIV Epidemic Initiative (EHE\nInitiative), which has the goal of reducing new HIV infections by 90% by 2030. Additionally, the HIV\nNational Strategic Plan: A Roadmap to End the Epidemic has been developed. We urge Congress to\ncapitalize on the expertise developed by communities as part of the EHE Initiative so that we can\nimprove and expand the Initiative. Ending HIV by 2030 is possible, but resources are needed to\nachieve this goal. ", "title": "ABAC Funding Chart", "buttonUrl": "https://www.nastad.org/sites/default/files/Uploads/2021/fy2022_abac_chart_2.8.21.pdf", "mediaType": 1, "buttonText": "ABAC Fudning Chart", "isLeftAligned": true, "useBackgroundColor": false}, "widgetType": 23}, {"props": {"title": "Elected Officials"}, "widgetType": 103}], "requires_login": false, "widget_layout_type": 8, "custom_javascript": "", "custom_css": "", "disclaimer_text": "", "use_page_region": false, "can_access": true, "cannot_access_message": null}, {"id": 3080, "archived": false, "name": "Workforce", "action_center": 1681, "path": "/Workforce_/", "title": "", "page_restriction_type": 1, "widgets": [{"props": {"title": "Workforce", "content": "

IDSA and HIVMA promote the value of the ID and HIV workforce, and advocate at a federal level for improved compensation and increased resources to support training loan repayment and professional opportunities for ID/HIV physicians, health care professionals, researchers, and public health experts.

ID Physician Shortages

The ID and HIV workforces have been shrinking despite the crucial role they play in responding to public health emergencies that include the COVID-19 pandemic and in driving treatment, diagnostics, and vaccines innovations. In part, this is due to a significant compensation disparity between ID/HIV physicians and physicians who provide more procedure-based care. While updates to outpatient evaluation and management codes took effect in 2021, inpatient E/M codes remain outdated and do not reflect the complexity of care provided by ID/HIV physicians. As a result, staggering medical school debt has added pressure on young physicians to pursue more lucrative specialties at the same time that a strong ID/HIV physician workforce is needed.

As the numbers of physicians specializing in ID continues to fall short of need, nearly 200 million Americans live in areas with little or no access to an infectious diseases physician, according to \u201cWhere Is the ID in COVID-19?\u201d a study published on June 4, 2020, in the Annals of Internal Medicine. As the COVID-19 pandemic has spread across the nation, 2,499 of the 3,142 counties in America do not have a single infectious diseases physician.

HIV Clinician Shortages & the HIV Epidemic Loan-Repayment Program (HELP) Act

People living with HIV whose care is managed by expert HIV clinicians have better outcomes. Still, the number of people needing lifelong care for HIV grows, the number of HIV clinicians entering the field falls well short of demand. The Centers for Disease Control and Prevention have predicted a shortage of qualified HIV clinicians. One study found that 80% of counties in 14 southern states do not have an experienced HIV clinician, with the worst shortages in rural areas.

The HELP Act would incentivize and add support for qualified clinicians and dentists to enter the field of HIV medicine and dentistry. By authorizing a new program that would offer up to $250,000 in educational loan repayment to physicians, nurse practitioners, physician assistants, clinical pharmacists and dentists in exchange for up to five years of service in high-need areas, the legislation helps address the urgent need, made even greater by the pandemic, to ensure a robust and well-qualified ID and HIV physician and clinical workforce.

Action Needed

Fortifying the ID/HIV workforce is paramount to ensuring patients have access to lifesaving ID expertise to address the full range of infectious diseases. ID physician care has been found to improve patient outcomes, reduce length of hospital stay and reduce Medicare costs. Congress and the Administration should act swiftly to protect patient and public health during the COVID-19 pandemic and be prepared to respond to future public health emergencies by:

Fairly compensating ID/HIV physicians;
Providing financial support for the specialties taking on significant uncompensated work to respond to the pandemic;
Supporting loan repayment for infectious diseases and HIV clinicians;
Improving the J-1 Visa program.

Please check back for opportunities to help advance our ID/HIV workforce priorities.

"}, "widgetType": 4}, {"props": {"content": "Tweets by IDSAInfo \n